Clinical Trial Update: A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC [Phase 2]

View source ↗

Summary

Phase 2 study of HB0025 in combination with nab-paclitaxel as first-line therapy for triple-negative breast cancer, currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• HB0025
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Huabo Biopharm Co., Ltd. | Conditions: TNBC | Phase 2 | Status: ENROLLING_BY_INVITATION